science – Asia Tab

ACN Newswire

LUI Che Woo Prize donates RMB 250 million to support the development of Shanghai Jiao Tong University Zhangjiang Science Park, The new campus is named Lui Che Woo Science Park

20 12 月, 2022

HONG KONG, Dec 20, 2022 - (ACN Newswire via SEAPRWire.com) - Dr Lui Che-woo, Chairman of K. Wah Group (the "Group") and the founder of LUI Che Woo Prize - Prize for World Civilization ("LUI Che Woo Prize"), has donated RMB 250 million through the LUI Che Woo Prize to support the development of Shanghai Jiao Tong University ("SJTU") Zhangjiang Science Park and contribute to national science and technology development. To thank Dr Lui for his generous donation, the new campus will be named Lui Che Woo Science Park. The agreement signing ceremony was held in Hong Kong today, guests including HKSAR Chief Executive John Lee who gave a video speech; former Chief Executive Carrie Lam, Executive Director of K. Wah International Holdings Limited ("KWIH") Alexander Lui, Executive Director of KWIH and member of board of trustees of SJTU Paddy Lui, Secretary of the CPC SJTU Committee Yang Zhen Bin; and Vice President of SJTU Zhang An Sheng. Professor Lin Zhong Qin, President of SJTU, and other university leaders participated in the ceremony via webcast. After the ceremony, Professor Ding Kui Ling, Executive Vice President of SJTU, Academician of the Chinese Academy of Sciences and Dean of the Zhangjiang Institute for Advanced Study, delivered a keynote speech on China's Forefront Science and Technology Development through a live webcast to promote the exchange of science and technology development and ties between Shanghai and Hong Kong.A rendering of Lui Che Woo Science Park in completion.1. Lui Che Woo Science Park Block 1: AI Biomedicine Centre, DNA Storage and Research Centre; 2. Block 2: Integrated Scientific Innovation Research Centre; 3. Block 3: AI Cybersecurity Innovation Centre; 4. Block 4: Frontiers Science Centre for Transformative Molecules, Future Material Creation Centre; 5. Block 5: Ultra-Fast Science Centre; 6. Science Park Complex; 7. Teacher and student dormitory; 8. Teacher and student dormitory; 9. The adjacent Shanghai Synchrotron Radiation FacilityDr Lui Che-woo, Chairman of K. Wah Group and the founder of LUI Che Woo Prize - Prize for World Civilization (middle) and Yang Zhen Bin (2nd left), Secretary of the CPC SJTU Committee sign the donation agreement, accompanied by Alexander Lui (2nd right), Executive Director of K. Wah International Holdings Limited; Paddy Lui (1st right), Executive Director of K. Wah International Holdings Limited and member of board of trustees of SJTU; and Zhang An Sheng (1st left), Vice President of SJTU.Dr Lui Che-woo, Chairman of K. Wah Group and the founder of LUI Che Woo Prize - Prize for World Civilization (1st row – 2nd right), Yang Zhen Bin (1st row - 2nd left), Secretary of the CPC Shanghai Jiao Tong University ("SJTU") Committee, former chief executive Carrie Lam (1st row – 1st right), Zhang An Sheng (1st row – 1st left), Vice President of SJTU, take a group photo with the representatives from the LUI Che Woo Prize, members of board of trustees, and representatives from the SJTU.Dr Lui Che-woo, Chairman of K. Wah Group and the founder of LUI Che Woo Prize - Prize for World Civilization delivers a speech.John Lee, HKSAR Chief Executive, gives a video speechThe agreement signing ceremony was webcast live at the lecture hall of the "Lui Che Woo Science Park" of Shanghai Jiao Tong University.Nurture new generations of scientists with SJTU to benefit mankind through scientific research and development ("R&D")SJTU is a well-known comprehensive university located in Shanghai. It plays a crucial role in the national innovation strategy and supports technological development, with a profound impact on the future of China and the wellbeing of people. In 2014, President Xi Jinping expressed hope of developing Shanghai into a technological innovation hub. The National Development and Reform Commission and the Ministry of Science and Technology then accelerated the construction of a technological innovation centre in the Zhangjiang area. Located in Zhangjiang, Lui Che Woo Science Park will be key for SJTU as it actively plays a part in constructing a national science centre in the area, and from which to build a world-class R&D base by promoting technological innovation and extensive integration with economic and social development, thus further strengthening China's international presence and influence in relevant fields. Dr Lui Che-woo, Chairman of K. Wah Group and the founder of LUI Che Woo Prize - Prize for World Civilization said, "SJTU is recognised for being one of the premier education institutions in China. It is renowned both at home and abroad, and has the longest history - stretching more than 120 years. Moreover, it has nurtured countless talent with adherence to its motto of "Gratitude and Responsibility". I am looking forward to the development of Lui Che Woo Science Park as it gradually becomes an internationally influential technological innovation centre, creating synergies with large-scale national science facilities and pursuing new R&D breakthroughs with other science parks. This includes the Shanghai Synchrotron Radiation Facility ("SSRF") nearby, which is one of the world's top five synchrotron light source projects and is engaged in the creation of new materials from atomic and molecular structures that are the fundamental of science."Yang Zhen Bin, Secretary of the CPC SJTU Committee, thanked Dr Lui for his generous support for the university, and said, "Dr Lui Che-woo selflessly promotes the advancement of mankind and encourages technological innovation through extraordinary wisdom. His assistance in the development of Lui Che Woo Science Park will boost the national technological innovation strategy and education development at SJTU. Lui Che Woo Science Park will lead SJTU as it integrates into the Zhangjiang Comprehensive National Science Centre and participates in the construction of a globally influential technological innovation centre. Through the steadfast attention of Dr Lui Che-woo and his family, we believe that Lui Che Woo Science Park will grow into an innovative platform for cross-disciplinary research; achieving major scientific breakthroughs, attracting top and innovative talent and utilising industrial technologies. "Optimise R&D conditions to attract and train professionals and consolidate China's international position in the R&D field As the primary technological innovation centre in Shanghai and a top national high-tech base, Zhangjiang Science Park possesses sizeable and comprehensive facilities, platforms, and superb institutes. Lui Che Woo Science Park is positioned as a world-class influential technological innovation centre, and is set to create a strong cluster effect with other large-scale national scientific facilities in the area. It is expected to promote the leapfrog development of multiple disciplines in China, build a cutting-edge interdisciplinary research platform, and become the centre for gathering top scientists. Lui Che Woo Science Park covers a GFA of over 100,000 square meters, half of which is for R&D use. There are eight buildings in total, housing more than 1,200 researchers from various disciplines which includes approximately 600 researchers, postdoctoral fellows, and about 600 researchers with doctoral and master degrees. They will mainly focus on the R&D of health, biomedical engineering and new materials.Seven centres and one platform support interdisciplinary scientific researchLui Che Woo Science Park houses seven research centres, including the AI Biomedicine Centre, DNA Storage and Research Centre, Integrated Scientific Innovation Research Centre, AI Cybersecurity Innovation Centre, Frontiers Science Centre for Transformative Molecules, Future Materials Creation Centre and Ultra-Fast Science Centre. Upon completion, the park will facilitate the construction of the Zhangjiang Comprehensive National Science Centre and drive China's fundamental R&D and related industrial development in interdisciplinary fields, such as physics, materials, biology, medicine and network, and so on.To facilitate collaboration among the seven research centres, the Lui Che Woo Science Park has built a public instrument platform, which currently has 65 sets of equipment worth a total of RMB137 million. It also boasts around 1,300 square meters of laboratory space, which will help further raise the standard of fundamental technologies, including element, organic molecule and molecular function analysis; providing greater and broader technical support for SJTU in terms of the detection and characterisation of such areas as organic chemistry, pharmacy, life science, medicine and material science. Furthermore, the instruments are available for teachers and students at SJTU to build a user-oriented training system. Technical training and exchanges will also be held regularly.Collaborates with SSRF to realize research results at Frontiers Science Centre for Transformative Molecules ("FSCTM")The Lui Che Woo Science Park is adjacent to SSRF, which has one of the world's top five synchrotron light source projects. The two parties have formed a strategic partnership and will cooperate in research into new molecules and materials. SSRF possesses operations that comparable to powerful "super X-ray machines" and "super microscopes", which can be used for researching in medicine, physics, science and so on.With the support from SSRF, the FSCTM at Lui Che Woo Science Park has developed the ultra-fast in-situ characterization technology. Through molecular electricity catalysis, new substances or materials can be developed for applications in medicine, clean energy and green chemicals. In 2022, results from the research team at the centre have been published by top international academic journals, such as Nature and Science.Enhances technological innovation and assists the country in implementing innovation-driven development strategiesDr Lui shares President Xi Jinping's thoughts that "science and technology are having a profound impact on the future of the country as well as on people's wellbeing like never before". He believes that there is an urgency to strengthen technological innovation to help the country play a major role in implementing development strategies and accelerating the replacement of traditional strategies with new ones.Having participated in philanthropy for nearly half a century, Dr Lui has been focusing on the support for education sector to align with the pace of national development. In particular, he is keen on supporting advanced scientific research and development in recent years, with the hope of contributing to the growth of the country. Dr Lui donated RMB120 million to the School of Life Sciences at Peking University in 2017 and RMB200 million to Tsinghua University in 2018 for the construction of two new blocks at the Biomedical Sciences Building, demonstrating his commitment to boosting life sciences development. Following these two donations, Dr Lui donated RMB250 million to SJTU to fund the construction of Lui Che Woo Science Park to support China's new and high-tech research development.Dr Lui concluded, "I migrated to Hong Kong at the age of four and have established K. Wah Group for nearly seven decades. Having witnessed the achievements of our motherland and Hong Kong in the new century, I was buoyed to uphold the belief of 'giving back to society from which one has benefited'. Technology has been developing at a rocket pace and will serve as the lifeline to people and civilization in the future. I am honoured to support SJTU's establishment of Lui Che Woo Science Park, and I hope its cutting-edge facilities and talent will contribute to scientific research and development in Shanghai and across China. I believe that the collaboration and exchange with international scientific research institutions will also boost the stature of China's scientific research in the global arena."About LUI Chi Woo PrizeFounded by Dr Lui Che-woo in 2015, the "LUI Che Woo Prize - Prize for World Civilisation" is an annual, first of its kind international cross-sector innovative award for advancing world civilisation and inspiring people to build a more harmonious world. It aims to recognise and honour individuals or organisations all over the world for outstanding contributions and encourages the continuation of that work in three objectives: sustainable development of the world, betterment of the welfare of mankind and promotion of positive life attitude and enhancement of positive energy.For more details, please go to www.luiprize.org.About K. Wah GroupK. Wah Group was founded in 1955 by Dr Lui Che-woo, who transformed the company into a multinational corporation. Core businesses include property development and investment, entertainment and leisure resorts, hospitality and construction materials. The Group has a business presence in Mainland China, Hong Kong, Macau, Southeast Asia and major cities in the US. The Group includes two Hong Kong-listed flagships: K. Wah International Holdings Limited ("KWIH"; HK stock code: 00173) and Galaxy Entertainment Group Limited ("GEG"; HK stock code: 00027 and a member of the Hang Seng Index) and over 200 subsidiaries, includes Stanford Hotels International and K. Wah Construction Materials Limited.Website: http://www.kwah.comMedia Enquiries:K. Wah GroupHelen Cheung Tel: (852) 2960 3739 Email: helencheung@kwah.com Jenny Tse Tel: (852) 2960 3101 Email: jennytse@kwah.com Andrey Leung Tel: (852) 2960 3364 Email: andreyleung@kwah.com Fax: (852) 2811 9710Lui Che Woo Prize - Prize for World CivilizationBrenda Kan Tel: (852) 2960 3791 Email: brendakan@luiprize.orgStrategic Financial Relations LimitedIris Lee Tel: (852) 2864 4829 Email: iris.lee@sprg.com.hk Shelly Cheng Tel: (852) 2864 4857 Email: shelly.cheng@sprg.com.hk Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

ACN Newswire

Polymer protection for vaccines and drugs

9 12 月, 2022

TSUKUBA, Japan, Dec 9, 2022 - (ACN Newswire via SEAPRWire.com) - A biocompatible polymer could help deliver vaccines and drugs with reduced risk of the rare dangerous adverse reaction called anaphylaxis. Researchers at the National Institute of Advanced Industrial Science and Technology (AIST) in Japan have developed the polymer and performed preliminary tests, which they report in the journal Science and Technology of Advanced Materials.A liposome (left) containing a vaccine is commonly coated with polyethylene glycol (PEG) but it can trigger an allergic reaction to some recipients. A newly developed lipid (right) could serve as a safer, alternative liposome-coating while retaining the vaccine longer in the body.Until now, the polymer of choice for encasing and delivering vaccines has been poly(ethylene glycol) (PEG). This synthetic, flexible, water-soluble material has been used to surround some COVID-19 vaccines carried within the tiny spherical packages known as liposomes.Unfortunately, some recipients have suffered an anaphylactic reaction to PEG, in which the immune system mounts an allergic response to the foreign material. Symptoms of anaphylaxis range from minor skin irritations, to breathing difficulty, nausea and, in the worst cases, unconsciousness and sudden death.The alternative polymer is a form of fatty biomolecule called a lipid, and is conjugated to 2-methacryloyloxyethyl phosphorylcholine (MPC) polymer.This new substance spontaneously binds to the outside of liposome particles when mixed with them in water. Crucially, the polymer is not recognized by the antibodies that the body can generate in response to PEG, and tests suggest it does not stimulate any other antibodies that could cause an allergic reaction. This should allow coated liposomes containing a vaccine to be retained in the body for a longer time without being cleared by the immune system, in addition to avoiding anaphylaxis."We have also found that the polymer avoids other interactions with proteins in the blood that might otherwise interfere with its effects, and it also prevents liposomes from aggregating together," says molecular engineer Yuji Teramura of the AIST team.Tests confirm the coated liposomes can remain stable in storage for 14 days, sufficient for real clinical applications."All the indications suggest that our technology should be suitable for delivering vaccines into patients who develop anaphylaxis in response to PEG," Teramura concludes.The polymer must now be thoroughly tested in various real vaccine applications. The team is moving into this next crucial phase of the development process, prior to eventual clinical trials in humans.Provided the animal and subsequent clinical trials go well, the technology should offer opportunities for delivering drugs into the body, in addition to vaccines. Delivery systems such as liposomes are sometimes needed to protect drugs from biochemical processes that might degrade them. This can ensure that they reach the target disease tissues while remaining in their active form.Further informationYuji TeramuraNational Institute of Advanced Industrial Science and Technology (AIST)Email: y.teramura@aist.go.jpAbout Science and Technology of Advanced Materials (STAM)Open access journal STAM publishes outstanding research articles across all aspects of materials science, including functional and structural materials, theoretical analyses, and properties of materials. https://www.tandfonline.com/STAMDr Yasufumi NakamichiSTAM Publishing DirectorEmail: NAKAMICHI.Yasufumi@nims.go.jpPress release distributed by Asia Research News for Science and Technology of Advanced Materials. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

ACN Newswire

Revealing crystal structures robotically

2 12 月, 2022

TSUKUBA, Japan, Dec 2, 2022 - (ACN Newswire via SEAPRWire.com) - Researchers at the National Institute for Materials Science (NIMS) in Japan have automated a complex and labour-intensive process for analysing the results of X-ray diffraction studies, which are used to determine the structure of crystalline materials. The team described the development and application of their technique in the journal Science and Technology of Advanced Materials: Methods.By combining machine learning with robotic process automation, researchers automated a mathematical procedure that determines the structure of crystalline materials. (Credit: ktsdesign/123rf)X-rays fired at a crystal interact with the geometric arrangement of its particles and are diffracted in many directions in a complex pattern of rays that depends on the crystal's precise structure. Experts analyse the pattern and intensity of the diffracted X-rays to determine the crystal's internal arrangement. This is a powerful and widely used process for revealing the three-dimensional atomic structure of new materials.A well-established mathematical procedure, called Rietveld analysis, is used for interpreting X-ray diffraction data, but it is time-consuming and requires manual trial-and-error refinement of the results."To reduce human costs and resources, we have developed a robotic process automation (RPA) system that we apply to an existing Rietveld analysis program called RIETAN-FP," says Ryo Tamura of the NIMS team. "By using our new procedure, with the help of machine learning, we have succeeded in performing Rietveld analysis automatically," Tamura adds.The automation can be run on a personal computer and can reduce human error as well as greatly speed up the data analysis.Tamura explains that the field of materials science already relies on numerous graphical user interface (GUI) applications to calculate a material's properties, control experimental equipment, or analyse material data. He says that combining this new RPA and machine learning ability with these applications achieves a "closed loop" to automatically design and analyse materials with minimal human intervention.The researchers verified the accuracy of their procedure by analysing samples of powdered compounds whose crystal structures are already known. The ability to determine the structures from powdered samples is one of the great strengths of Rietveld analysis. It avoids the need to grow large single crystals, which can be extremely difficult to obtain for some materials."Automating Rietveld analysis brings a very powerful new tool into the entire field of materials science," Tamura concludes.The researchers are now working to further refine their procedure to make it suitable for more complex crystal structures. Another aim is to explore the use of their machine learning RPA strategy for more general applications in materials science. The possibilities include numerous simulation methods used for calculating material properties, and also applications for controlling experimental equipment. The success achieved thus far with X-ray diffraction could just be the start for Rietveld robotics.Further informationRyo Tamura National Institute for Materials ScienceEmail: tamura.ryo@nims.go.jpAbout Science and Technology of Advanced Materials: Methods (STAM Methods)STAM Methods is an open access sister journal of Science and Technology of Advanced Materials (STAM), and focuses on emergent methods and tools for improving and/or accelerating materials developments, such as methodology, apparatus, instrumentation, modeling, high-through put data collection, materials/process informatics, databases, and programming. https://www.tandfonline.com/STAM-MDr. Yasufumi NakamichiSTAM Methods Publishing DirectorEmail: NAKAMICHI.Yasufumi@nims.go.jpPress release distributed by Asia Research News for Science and Technology of Advanced Materials. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

JCN Newswire

Fujitsu Spain receives 9th award of the “Fundación Consejo España-Japón” (Spain-Japan Foundation)

5 10 月, 2022

TOKYO, Oct 5, 2022 - (JCN Newswire via SEAPRWire.com) - Fujitsu today announced that its Spanish subsidiary, Fujitsu Spain, was awarded the 9th award of the Fundación Consejo España-Japón (Spain-Japan Foundation, hereinafter FCEJ)(1) in recognition of its energetic business development and strong commitment to Spanish society and its continuous efforts in promoting the country's digitalization.Fujitsu Spain, which was established in 1973, will celebrate the 50th anniversary of its foundation in 2023.As a DX company, Fujitsu Spain will continue to strengthen its cooperation with the country to promote businesses focused on solving societal issues.Josep Piqué, President of the FCEJ comments:"Fujitsu Spain will celebrate its 50th anniversary in 2023, and has become one of the Japanese companies that has contributed the most to Spain over the years. Fujitsu is a global leader in providing the necessary know-how in digital transformation to advanced economies. I would like to express my sincere congratulations on Fujitsu's energetic business development and contribution to society."About the FCEJ AwardSince 2011, the FCEJ presents annual awards to individuals and organizations in Spain and Japan who have contributed to the promotion of deeper knowledge and relations between the two countries in various fields.The award ceremony will be held at the 22nd Foro España-Japón (Spain-Japan Forum) at the Keihanna Science City (2) on October 5, 2022.Fujitsu, 50 years of history and experience in Spain- 1973: First office established in Madrid; started to provide solutions for public and financial institutions- 1984: Established a factory in Malaga to manufacture ATMs for the global market- 1996: Started production of automotive components- 2016: Established European big data analytics center in Madrid- 2022: Provided environment for the use of Fujitsu's quantum-inspired Digital Annealer to the Madrid University of Technology(1) Fundación Consejo España-Japón (Spain Japan Foundation) :Head Office: Spain Madrid; President: Josep Pique(2) Keihanna Science City :Located in the Keihanna hills stretching over the three prefectures of Kyoto, Osaka, and Nara; constructed and maintained under the Kansai Science City Construction Act. Along with 'Tsukuba Science City' in East Japan, Keihanna Science city is positioned as a national project, having a total area of approximately 15,000 hectares, within which 12 cultural and academic research zones (approximately 3,600 hectares) are distributed.About FujitsuFujitsu's purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers in over 100 countries, our 124,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: Computing, Networks, AI, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.6 trillion yen (US$32 billion) for the fiscal year ended March 31, 2022 and remains the top digital services company in Japan by market share. Find out more: www.fujitsu.com. Copyright 2022 JCN Newswire. All rights reserved. (via SEAPRWire)

ACN Newswire

Malaysian Genomics, Rinani Genotec Sign LOI with Universiti Malaysia Sabah

21 9 月, 2022

PETALING JAYA, Malaysia, Sep 21, 2022 - (ACN Newswire via SEAPRWire.com) - Leading genomics and biopharmaceutical specialist Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155) is pleased to report that the Group has signed a letter of intent (LOI) with the Faculty of Science and Natural Resources, Universiti Malaysia Sabah (UMS) and Rinani Genotec Sdn Bhd (Genotec) to collaborate on research and development (R&D) in genetics, and regenerative and alternative medicines.Chairman of Malaysian Genomics, Datuk Seri Dr. Chen Chaw MinUnder the LOI, MGRC, which owns a high-throughput sequencing lab, advanced microarray facility, and new state-of-the-art cell processing lab, as well as Genotec, which specializes in biomedical treatments using stem cells, will assist in strengthening the teaching and research activities of the undergraduate programme at UMS' Faculty of Science and Natural Resources.This cooperation will enable the exchange of research resources and ideas to enhance the quality of research at UMS, as well as create opportunities for students from the Faculty of Science and Natural Resources to serve their internship period at MGRC or Genotec.Chairman of Malaysian Genomics, Datuk Seri Dr. Chen Chaw Min, said, "We are happy to assist UMS undergraduates in pursuing their R&D goals so that they have a better understanding of their field of study. This is also in support of the National Biotechnology Policy 2.0 launched recently focusing on agriculture and food security, healthcare and wellbeing, as well as industrial and the circular economy."The Dean of the Faculty of Science and Natural Resources, UMS, Professor Dr. Jualang Azlan Gansau said, "UMS is actively engaging in research as well as teaching activities and the involvement of industry is crucial in ensuring the relevance of such activities conducted at the University."The signing of the LOI followed UMS' visit to MGRC's Biosafety Level 2 cGMP (Current Good Manufacturing Practice)-certified laboratory, which is used for the production of cell therapies, including CAR T-cell therapies for various cancers.Malaysian Genomics Resource Centre Berhad: 0155 [BURSA: MGRC] [RIC: MGRC:KL] [BBG: MGRC:MK], http://www.mgrc.com.my/ Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

ACN Newswire

SinoMab Received the Highest Subsidy from HKSTP

8 7 月, 2022

HONG KONG, Jul 8, 2022 - (ACN Newswire via SEAPRWire.com) - SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-listed biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of innovative therapeutics for the treatment of immunological diseases, primarily mAb-based biologics, is pleased to announce that, the Company has received HK$8 million subsidy from the Hong Kong Science and Technology Parks Corporation ("HKSTP"), which is the highest subsidy amount in the Clinical Translational Catalyst (CTC) program of HKSTP.CTC program is offered by HKSTP Institute for Translational Research (ITR), the overarching aim is to provide a platform to transform Hong Kong and Greater Bay Area to become the go-to destination for translational medicine in the region. Under this program, funding support will be provided to biomedical companies of HKSTP to bring innovative, life-changing therapies and technologies to patients.SinoMab stood out from many biopharmaceutical companies in the CTC program and was granted the highest subsidy amount, embodying the recognition by the evaluation committee on the Company's product candidates and research and development (R&D) plan. According to the agreement signed by both parties, HKSTP will provide SinoMab a subsidy of HK$8 million in the next 42 months in phases according to its clinical plan and progress for the clinical study of SN1011, the Company's key product, for the treatment of multiple sclerosis (MS). SN1011 is SinoMab's key product and third-generation covalent reversible Bruton's tyrosine kinase (BTK) inhibitor. Following the approval of Investigational New Drug (IND) applications of SN1011 for systemic lupus erythematosus (SLE) and pemphigus vulgaris (PV) by the National Medical Products Administration (NMPA) on 27 August 2020 and 23 June 2021, respectively, the IND application of SN1011 for MS has been approved by the NMPA on 19 April 2022. The Company plans to initiate Phase II clinical study to evaluate the efficacy and safety of SN1011 in patients with MS in China and expects to enroll the first patient in the fourth quarter of 2022. The IND application of SN1011 for neuromyelitis optica spectrum disorder (NMOSD) was also accepted by the Center for Drug Evaluation (CDE) of the NMPA on 6 June 2022.Dr. Shui On LEUNG, Chairman, Executive Director and Chief Executive Officer of SinoMab said that: "By launching the CTC program, HKSTP provides great support to local biopharmaceutical companies on their New Drug R&D. As a biopharmaceutical company raised in Hong Kong for 20 years, we are grateful for the long-term support and assistance of the HKSTP in promoting innovation and development of local biopharmaceutical companies. Previously, President Xi Jinping, and the Chief Executive of the HKSAR, Mr. Lee Ka-chiu, visited the Science Park, with the desire to forge Hong Kong into an international Innovation and Technology hub, demonstrating the country's high appreciation of Hong Kong innovative technology development. We are excited by the unprecedented opportunities. With the smooth progress of clinical trials of the Company's key candidates, the subsidy from the HKSTP will provide a solid foundation for the Company's continuous R&D and stepping toward commercialization. We will fully grasp the opportunity to accelerate the R&D and clinical trials of various products, further expand the product pipeline and potential indications, speed up the realization of product commercialization, adhere to the concept of independent innovation, strive for the well-being of patients and create value for shareholders."About Hong Kong Science and Technology Parks CorporationEstablished in 2001, HKSTP attracts and nurtures talent, accelerates and commercializes innovation and technology for entrepreneurs on their journey of growth in Hong Kong, to the Greater Bay Area, Asia and beyond. Its growing innovation ecosystem is built around its key locations of the Hong Kong Science Park in Shatin, InnoCentre in Kowloon Tong and three modern INNOPARKs in Tai Po, Tseung Kwan O and Yuen Long. The three INNOPARKs are realizing a vision of re-industrialisation for Hong Kong. The goal is sectors like advanced manufacturing, electronics and biotechnology are being reimagined for a new generation of the industry. Through its infrastructure, services, expertise and network of partnerships, HKSTP will help establish innovation and technology as a pillar of growth for Hong Kong, while reinforcing Hong Kong's international I&T hub status as a launchpad for global growth at the heart of the GBA innovation powerhouse.About SinoMab BioScience LimitedSinoMab BioScience Limited (stock code: 3681.HK) is dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases. The Company's flagship product SM03 is a potential global first-in-target mAb against CD22 for the treatment of rheumatoid arthritis (RA) and is currently in Phase III clinical trial for RA in China, which has been recognized as one of the significant special projects of Significant New Drugs Development of the Twelfth Five-Year Plan Period and the Thirteenth Five-Year Plan Period. In addition, the Company possesses other potential first-in-target and first-in-class drug candidates, some of which are already in clinical stage, with their indications covering rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), pemphigus vulgaris (PV), non-Hodgkin's lymphoma (NHL), asthma, and other diseases with major unmet clinical needs. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

JCN Newswire

Fujitsu Commits to the UK’s Science and Technology Superpower Potential

15 6 月, 2022

TOKYO, Jun 15, 2022 - (JCN Newswire via SEAPRWire.com) - Forty years since Fujitsu began its presence in the UK, the company has committed to a major program of investment to establish the UK in a key position in its global innovation network. Fujitsu is determined to bring further innovation to the UK and will see the creation of over 200 high skilled jobs over the next year. This will add to the great bridge of innovation connecting the UK and Japan, which the UK Minister for Investment, Lord Grimstone described in his speech at Lancaster House (14.06.2022) when announcing this investment.During London Tech Week Fujitsu is setting out the first phase of this investment with an initial EUR22 million to establish its Center for Cognitive and Advanced Technologies (C-CAT), with the first projects already underway in the North West of England. The C-CAT's foundation is an important milestone in Fujitsu's global technology innovation strategy. The Center will import emerging technology from Japan, serve as a catalyst for cross-sectoral innovation and wider Fujitsu transformation, focused on the commercialization of research and partner collaboration. It will form a foundation to direct future investment.The announcement follows the strengthening of the relationship between the UK and Japan since the signing of the Free Trade Agreement in October 2020. The FTA enables greater collaboration in science and technology between the two countries, which together with the UK Government's commitment to maintain and enhance the UK's status as a science and technology superpower helped attract this initial investment, with further announcements planned later this year.Visiting London Tech Week, Fujitsu's Global CTO, Vivek Mahajan said: "Fujitsu is committed to and has confidence in the UK. We share the UK Government's ambitions to thrive as a science and technology superpower. We recognize the potential of the growing partnership between the UK and Japan, and we will look to contribute to this by building the C-CAT as an innovation bridge between the two countries. The establishment of the Center for Cognitive and Advanced Technologies here demonstrates the UK's importance in our global mission to create a more sustainable world through innovation."UK Government Minister for Investment, Lord Grimstone said: "Fujitsu's decision to invest '22 million to build its new Center here in the UK is testament to our business-friendly environment, will create 200 jobs and strengthen the great bridge of innovation connecting the UK and Japan. This project supports our shared ambition to maintain the UK's status as a science and technology superpower and enhance our world-leading work in key areas such as AI and quantum computing for the modern digital and data-driven economy."The initial EUR22 million investment will establish the C-CAT to bring together Fujitsu's activity on a range of emerging technologies including quantum, AI, and digital twin technology, providing a direct link to work in Japan so that the UK can benefit from Japan's leadership in areas such as supercomputing with Fujitsu's work on Fugaku, one of the world's fastest supercomputers -- while Fujitsu benefits from working with the UK's thriving research and innovation ecosystem.The C-CAT will be led by Emerging Technology expert Dr Keith Dear and will see Fujitsu investing in skills alongside advanced technologies. As part of this investment, Fujitsu will explore further opportunities to leverage its quantum inspired Digital Annealer technology in the UK. Fujitsu's world leading quantum inspired technologies have already brought benefits to UK partners such as the UK Space Agency. Bringing this technology on-shore and on premises in the UK will deliver greater benefits to UK industry and the public sector adding to long term needs for sustainability and resilience.Operating initially from Fujitsu's offices in Manchester and drawing on Fujitsu's long-partnership and Explainable AI-work with the University of Manchester, the C-CAT will expand into a permanent campus built on co-creation to solve major challenges through innovation for the benefit of business, government, and society. The final location of C-CAT's campus will be determined after a rigorous evaluation and announced in the Autumn.Head of Fujitsu UK, Anwen Owen stated: "By committing to a series of investments we are showing our confidence in the UK for the long term. Fujitsu is placing the UK at the heart of its approach to innovation globally. This initial investment has the potential to grow over the coming years as we build our capability in cognitive and advanced technologies such as quantum, AI and digital twin -- to support our goal to revolutionize how individuals and organizations make decisions. The establishment of the Center for Cognitive and Advanced Technologies is just the first step in expanding our UK presence, investing in digital talent and emerging technologies so we can contribute to the UK's science and technology superpower potential."Following the establishment of the C-CAT Fujitsu will set out details of the second phase of growing its commitment to the UK later this year with more ambitious plans into 2023.Fujitsu's Commitment to the Sustainable Development Goals (SDGs)The Sustainable Development Goals (SDGs) adopted by the United Nations in 2015 represent a set of common goals to be achieved worldwide by 2030. Fujitsu's purpose -- "to make the world more sustainable by building trust in society through innovation" -- is a promise to contribute to the vision of a better future empowered by the SDGs.About FujitsuFujitsu's purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers in over 100 countries, our 124,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: Computing, Networks, AI, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.6 trillion yen (US$32 billion) for the fiscal year ended March 31, 2022 and remains the top digital services company in Japan by market share. Find out more: www.fujitsu.com. Copyright 2022 JCN Newswire. All rights reserved. (via SEAPRWire)